Fluoxetine - CAS:54910-89-3

您当前的位置：

Fluoxetine (Synonyms:氟西汀; LY-110140 free base)

目录号 : KM19318 CAS No. : 54910-89-3

Data Sheet 产品使用指南

Fluoxetine (LY-110140 free base) 是选择性 5-羟色胺再吸收抑制剂 (SSRI)。

规格	价格	是否有货	数量
25mg		In-stock
50mg		In-stock
100mg		In-stock
500mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Lamotrigine-d3 In-stock
Apatinib-d8 In-stock
BRD5631 In-stock
AMDE-1 In-stock
MDK-6983 In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

体外研究

Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration.

体内研究

Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone.

分子式

C₁₇H₁₈F₃NO

分子量

309.33

CAS号

54910-89-3

中文名称

氟西汀

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

溶解性数据

In Vitro:

DMSO : 100 mg/mL (323.28 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2328 mL	16.1640 mL	32.3279 mL
5 mM	0.6466 mL	3.2328 mL	6.4656 mL
10 mM	0.3233 mL	1.6164 mL	3.2328 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO→40% PEG300→5% Tween-80→45% saline

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.72 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO→90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.72 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO→90% corn oil

Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.72 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。